BR112018002139A2 - combinações de inibidor de tirosina quinase de bruton e usos da mesma - Google Patents

combinações de inibidor de tirosina quinase de bruton e usos da mesma

Info

Publication number
BR112018002139A2
BR112018002139A2 BR112018002139A BR112018002139A BR112018002139A2 BR 112018002139 A2 BR112018002139 A2 BR 112018002139A2 BR 112018002139 A BR112018002139 A BR 112018002139A BR 112018002139 A BR112018002139 A BR 112018002139A BR 112018002139 A2 BR112018002139 A2 BR 112018002139A2
Authority
BR
Brazil
Prior art keywords
tyrosine kinase
kinase inhibitor
bruton tyrosine
inhibitor combinations
combinations
Prior art date
Application number
BR112018002139A
Other languages
English (en)
Portuguese (pt)
Inventor
Chang Betty
James Danelle
Chen Jun
Jeff Hsu Ssucheng
Kinoshita Taisei
Huang Yujun
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of BR112018002139A2 publication Critical patent/BR112018002139A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112018002139A 2015-07-31 2016-07-29 combinações de inibidor de tirosina quinase de bruton e usos da mesma BR112018002139A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562199852P 2015-07-31 2015-07-31
US201562221499P 2015-09-21 2015-09-21
US201562243432P 2015-10-19 2015-10-19
PCT/US2016/044916 WO2017023815A1 (en) 2015-07-31 2016-07-29 Bruton's tyrosine kinase inhibitor combinations and uses thereof

Publications (1)

Publication Number Publication Date
BR112018002139A2 true BR112018002139A2 (pt) 2018-09-11

Family

ID=57885762

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018002139A BR112018002139A2 (pt) 2015-07-31 2016-07-29 combinações de inibidor de tirosina quinase de bruton e usos da mesma

Country Status (10)

Country Link
US (2) US20170027941A1 (enExample)
EP (1) EP3328380A4 (enExample)
JP (1) JP2018522028A (enExample)
CN (1) CN108024996A (enExample)
AU (1) AU2016303659A1 (enExample)
BR (1) BR112018002139A2 (enExample)
CA (1) CA2994161A1 (enExample)
MA (1) MA42546A (enExample)
MX (1) MX2018001369A (enExample)
WO (1) WO2017023815A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
JP2019206516A (ja) * 2018-05-23 2019-12-05 国立大学法人高知大学 膵癌細胞の浸潤転移抑制剤
TWI787523B (zh) * 2018-06-15 2022-12-21 漢達生技醫藥股份有限公司 達沙替尼十二烷基硫酸鹽之結晶
CN111053777A (zh) * 2018-10-16 2020-04-24 正大天晴药业集团股份有限公司 伊布替尼的药物组合物及其应用
CN111419853B (zh) * 2020-05-27 2022-07-19 德立唯（北京）生物科技有限公司 一种治疗乳腺癌的葫芦素与依鲁替尼组合物
US11433072B1 (en) * 2021-06-10 2022-09-06 Hikma Pharmaceuticals USA, Inc. Oral dosage forms of ibrutinib
CN115671110B (zh) * 2021-07-30 2024-05-10 上海云晟研新生物科技有限公司 帕唑帕尼口服药物组合物、其制备方法及应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
CN103221042B (zh) * 2010-06-02 2016-02-10 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
MX380504B (es) * 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
SG11201503459SA (en) * 2012-11-02 2015-06-29 Pharmacyclics Inc Tec family kinase inhibitor adjuvant therapy
US20160287592A1 (en) * 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
EP2832358A1 (en) * 2013-08-02 2015-02-04 Bionsil S.r.l. Pharmaceutical kit for use in the treatment of colon and colorectal cancer
CA2920534A1 (en) * 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
EA201690987A1 (ru) * 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
WO2016123504A1 (en) * 2015-01-30 2016-08-04 Pharmacyclics Llc Btk inhibitor combinations and multidrug-resistance

Also Published As

Publication number Publication date
US20200030330A1 (en) 2020-01-30
EP3328380A1 (en) 2018-06-06
MX2018001369A (es) 2018-11-29
WO2017023815A1 (en) 2017-02-09
JP2018522028A (ja) 2018-08-09
AU2016303659A1 (en) 2018-02-22
MA42546A (fr) 2018-06-06
CA2994161A1 (en) 2017-02-09
US20170027941A1 (en) 2017-02-02
CN108024996A (zh) 2018-05-11
EP3328380A4 (en) 2019-07-24

Similar Documents

Publication Publication Date Title
BR112017002232A2 (pt) combinações de inibidor de tirosina quinase de bruton e usos das mesmas
PT3658557T (pt) Inibidores de tyk2 e usos dos mesmos
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
MA42242A (fr) Inhibiteurs de la tyrosine kinase
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
DK3303334T3 (da) Tyrosinkinasehæmmere
BR112017009204A2 (pt) Derivados de feniltriazol hidroxialquil- substituído e usos dos mesmos
MA43162A (fr) Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
BR112017018931A2 (en) pharmaceutical formulations of a bruton tyrosine kinase inhibitor
EP3442972A4 (en) BROMDOMÄNENINHIBITOREN
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
EP3405192A4 (en) BRUTON TYROSINE KINASE HEMMER
BR112017020743A2 (pt) cocristais de um inibidor da tirosina cinase de bruton.
BR112017026559A2 (pt) ceratoprótese e usos dos mesmos.
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
DK3288931T4 (da) Visse proteinkinaseinhibitorer
CL2015003493S1 (es) Mueble.
EP3543239C0 (en) SELECTIVE INHIBITOR OF BRUTON'S TYROSINE KINASE AND ITS USE
BR112017015618A2 (pt) inibidores de mir-92 e usos destes.
EP3555092A4 (en) PROTEIN KINASE INHIBITORS
EP3340806A4 (en) STEVIA EXTRACTS
BR112017022691A2 (pt) inibidor de bromodomínio.
EP3454852A4 (en) PHOSPHOTIDYLINOSITOL 3-KINASES INHIBITORS
EP3511327A4 (en) TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements